Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
Journal for Immunotherapy of Cancer|June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockadeRikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growthLing Liu, Wei Zeng, Mark A Wortinger, et al.
Molecular Cancer Therapeutics|February 4, 2021
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung CancerJens Köhler, Yutong Zhao, Jiaqi Li, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Oncotarget|February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitorJonathan M Yingling, William T McMillen, Lei Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer ImmunotherapyDavid A Schaer, Sandaruwan Geeganage, Nelusha Amaladas, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 2